PubMed Health⌕ Search

Biomedical subjects

R D Lloyd

Publications and source records attributed to R D Lloyd.

At least 91 records · Page 5Linked to original sources
PubMed1986

Changes in body composition and dietary intake after gastric partitioning for morbid obesity.

Patients who undergo gastric partitioning for morbid obesity lose weight rapidly in the first year after surgery. This study measured changes in body composition and dietary intake at 3 months, 6 months, and 1 year after gastric partitioning. Body composition was determined by total-body gamma-ray spectrometry. Records of dietary intake were computer analyzed for nutritional content with the Ohio State Nutrient Analysis Data Base. All patients lost a significant amount of weight at 3, 6, and 12 months after surgery. Loss of lean tissue comprised 25% of the total weight loss at 3 months but only 20% of the total at 1 year. Before surgery the mean energy intake was 2592 kcal and the mean protein intake was 92 gm. After 3 months, energy intake was 745 kcal and protein 32 gm. One year after surgery energy intake was 1089 kcal and protein 41 gm per day. We conclude that patients lose a significant amount of lean body tissue in the first 3 months after gastric partitioning but the loss does not continue, and 1 year after surgery some lean tissue is actually regained. This initial loss is due to a combination of a very restrictive dietary regimen and the body's metabolic response to surgery. After the first 3 months adaptation occurs and lean tissue is spared.

Adult↗
PubMed1985

Effect of Zn-DTPA therapy on the maternal transfer of 241Am or 237Pu to young mice.

Newborn mice exposed to 241Am or 237Pu during gestation and whose mothers were given Zn-DTPA at various times before parturition contained less radioactivity than comparable newborn mice given identical 241Am or 237Pu exposure without Zn-DTPA treatment of the mothers. There was no net increase in radionuclide transfer from mothers to unborn young as a result of maternal administration of Zn-DTPA, regardless of the pregnancy stage during which the radioactivity and decorporation treatments were given. Administration of 241Am followed after three days by extended Zn-DTPA therapy resulted in lower fetal content of radioactivity in litters conceived long after or soon after maternal exposure to 241Am. These data indicate that the risk from Am and Pu to unborn young can be reduced by Zn-DTPA treatment of the pregnant mother and of the female who becomes pregnant subsequently. This information may prove to be of significance with the increasing probability of Am or Pu exposure to women in the nuclear industry who could be pregnant at the time or who may conceive a child in the future.

Americium↗
PubMed1985

Effect of age on the efficacy of Zn-diethylenetriaminepentaacetic acid therapy for removal of Am and Pu from beagles.

Decorporation of intravenously injected monomeric 241Am and 237+239Pu by the administration of 30 mumole Zn-diethylenetriaminepentaacetic acid (DTPA)/kg each day beginning 2 weeks after radionuclide injection was compared in beagles entered into the experiment when 3 months (juveniles). 1.9 years (young adults), or 10 years (mature adults) old and studied for about 5 months. DTPA therapy was most effective in the juvenile dogs and least effective in the mature adults. Retention of 241Am in the liver decreased from a pretreatment value for adults of about 50% of the injected activity to about 10% in the mature adults and less than 1% in the young adults at 140 days of treatment, while the liver retention of juveniles decreased from pretreatment values of about 16% to undetectable levels by 28 days of treatment. Plutonium retention in the liver decreased from adult pretreatment levels of about 30% of the injected activity (corrected for radioactive decay) to near 10% in the mature adults and 6% in the young adults at 140 days of treatment, while juvenile liver retention decreased from pretreatment values near 15% to undetectable levels by 56 days of treatment. Nonliver Am retention (mainly skeleton) decreased in mature adults from pretreatment values of about 45% of the injected activity to near 25%, in young adults from 35 to 20%, and in juveniles from roughly 70 to 9% by 140 days of DTPA administration. Nonliver Pu retention decreased from pretreatment values of about 50% of the injected activity (corrected for radioactive decay) for mature and young adults to about 30% by 140 days and from 75 to 16% in juveniles over the time period.

Aging↗
PubMed1985

243,244Cm studies in C57BL/Do mice.

Three groups of C57BL/Do mice were injected with different activities of 243,244Cm so that the long-term biological effects could be evaluated. The biological retention, R, of injected curium in the skeleton at t days after injection could be represented by the equations R = 0.245e-0.000379t and R = 0.208e-0.000494t for male and female mice, respectively. Effective skeletal retention equations were used to calculate the cumulative mean skeletal dose in rad at 140 days before death in each group of mice. The primary objective of this study was to determine the relative biological effectiveness (RBE) of 243,244Cm compared to 226Ra, using bone sarcoma induction as the end point. Combined data (bone sarcomas per 10(6) mouse-rad) for male and female mice permitted the RBE value +/- SD for 243,244Cm to be calculated as 4.4 +/- 1.8 compared to 1.0 for 226Ra. A comparison of RBE values form a previous study in this mouse strain and the value for 243,244Cm from this study suggests that the trivalent actinides 241Am, 243,244Cm, and 249Cf are about three times less effective for bone sarcoma induction than 239Pu.

Animals↗
PubMed1984

228Th retention and dosimetry in beagles.

Total-body and skeletal retention of 228Th were determined in a group of 104 young adult male and female beagles for about the first 7 years after the injection of 0.00159 to 2.76 muCi/kg. Ratios of 224Ra / 228Th , 212Pb / 228Th , and 212Bi / 228Th in the skeleton and in soft tissues of 20 beagles were measured as a function of time after injection. A humerus, femur, and ulna from 20 dogs dying 7 to 554 days after injection were sectioned, and the 228Th concentration was obtained for each piece. Percentage biological retention in the skeleton of 228Th at t days after injection could be described as 68.1 e-0. 000180t . Ratios of daughter-to-parent activity in soft tissue showed no definite trend with dose level or time and averaged Ra/Th = 0.56, Pb/Th = 0.83, and Bi/Th = 0.91, whereas the ratios for the skeleton varied with both dose level and time. Ratios of activity in the skeleton from lowest to highest dose level after 2 years following injection ranged between Ra/Th = 0.88 to 0.95, Pb/Th = 0.78 to 0.92, and Bi/Th = 0.77 to 0.90. Retained 228Th was deposited most heavily in parts of the skeleton with much trabecular bone, much bone surface area, and high bone remodeling rates. No changes in this deposition pattern could be discerned during the 554 days over which the measurements of sectioned long bones were made.

Animals↗
PubMed1984

Retention and dosimetry of injected 241Am in beagles.

Equations have been derived, from the results of total-body and partial-body counting and gamma-ray counting of individual bones and soft tissues, which describe the retention of injected 241Am in the liver, in the nonliver tissue (including skeleton), and in the skeleton of young adult beagles. Retention was found to be dependent upon injection level, and different sets of equations were developed for dogs given about (a) 2.8 microCi/kg (b) 0.9 microCi/kg (c) 0.3 microCi/kg, and (d) 0.1 microCi/kg and less. Liver rention, RL, was characterized by a single exponential equation of the form RL = ce-beta t, with c = 0.49 +/- 0.04 and beta = a function of injection level. Nonliver tissue was assigned a retention equation of the form RNL = d + alpha + J(l - e-mt), with d = 0.102 +/- 0.024 e-1.22t, alpha = 0.41 +/- 0.04, and both J and m as a function of injection level. Skeletal retention was found to be about 0.885 +/- 0.037 of nonliver retention with no significant dependence upon either injection level or time after 241Am injection. Dosimetry equations based on these retention expressions were derived. Individual bones of 55 beagles were assayed at death for their 241Am content for a determination of 241Am distribution within the skeleton.

Americium↗
PubMed1984

Removal of Pu and am from beagles and mice by 3,4,3-LICAM(C) or 3,4,3-LICAM(S).

Decorporation of Pu and Am by tetrameric catechoylamide (CAM) ligands has been investigated in beagles and mice. Eight dogs were injected intravenously (iv) with 237 + 239Pu(IV) + 241Am(III) citrate, and 30 min later, pairs of dogs were injected iv with 30 mumole/kg of 3,4,3-LICAM(C) [N1,N5,N10,N14-tetrakis(2,3-dihydroxy-5-sulfobenzoyl)tetr aazatetradecane, tetrasodium salt], 3,4,3-LICAM(S) [N1,N5,N10,N14-tetrakis(2,3-dihydroxy-4-carboxybenzoyl)te traazatetradecane, tetrasodium salt], CaNa3-DTPA, or each of the latter two ligands. Blood was sampled, and excreta were collected for 7 days, at which time the dogs were sacrificed and nuclide retention in liver and nonliver tissue was measured. Groups of five mice were each given 238Pu(IV) or 241Am(III) citrate iv; 3 min later 30 mumole/kg of a CAM ligand was injected intraperitoneally, mice were killed at 24 hr, and separated excreta and tissues were analyzed. In the dogs, average retention at 7 days of the injected Pu and Am, respectively, was as follows: 12 and 70% after treatment with a CAM ligand alone; 30 and 20% after DTPA; 12 and 20% after LICAM(S) plus DTPA; 90 and 89% without a ligand. In the mice, mean retention of the injected Pu and Am, respectively, was as follows: 14 and 66% after treatment with LICAM(C); 21 and 54% after LICAM(S); 91 and 87% without a ligand. In both species, about 99% of net Pu excretion (excretion with ligand - excretion without ligand) promoted in 24 hr by DTPA or LICAM(S) was in the urine, whereas about 10% of net Pu excretion promoted by the less hydrophilic LICAM(C) was in feces. Delayed excretion of both Am and Pu was significant in all ligand-treated dogs. Comparison of the nuclide content of tissues of ligand-treated mice with those of mice killed 3 min after nuclide injection indicated that the CAM ligands chelated circulating Pu and Am and prevented further deposition. In addition, the CAM ligands removed much of the presumably loosely bound Pu present in liver and skeleton at the time of ligand injection. LICAM(C) was more effective in removing Pu from liver and LICAM(S) was more effective in the skeleton. Moderate to severe uremia and histological evidence of cell killing in the distal tubules of the kidney were observed in the four dogs injected once with 30 mumole/kg of LICAM(S).(ABSTRACT TRUNCATED AT 400 WORDS)

Americium↗
PubMed1983

Skeletal retention and distribution of 226Ra and 239Pu in beagles injected at ages ranging from 2 days to 5 years.

The age at exposure significantly affects the retention and distribution of 226Ra and 239Pu, both of which deposit in the skeleton although in somewhat different patterns. Beagles aged 2 days (neonates), 90 days (juveniles), 18 months (young adults), or 5 yrs (mature) received a single subacute injection of one of these nuclides and were sacrificed serially during a 2-yr interval. Nuclide concentrations in plasma, the skeleton, individual bones and bone sections were determined and retention equations were calculated. The microanatomical skeletal nuclide distribution was studied after fission track or conventional autoradiography. Elimination of 239Pu and its translocation from bone surfaces to the bone volume caused by bone growth and turnover processes were measured. Average radiation doses and dose rates as a function of age at exposure were determined. Initial uptake and retention, skeletal nuclide concentration, proliferative activity of local cell populations and residence time of the nuclide on skeletal surfaces were affected significantly by age at exposure. The effect of these parameters on tumor induction is discussed. This study has provided early retention and distribution data which together with data from a chronic toxicity study will be used to estimate the risk of Pu exposure relative to that of Ra to humans of all ages.

Aging↗
PubMed1983

Comparative toxicity of 226Ra, 239Pu, 241Am, 249Cf, and 252Cf in C57BL/Do black and albino mice.

Groups of C57BL/Do (black and albino) mice were injected with graded activities of 226Ra, 239Pu, 241Am, 249Cf, or 252Cf and were followed throughout life. Bone sarcoma was the principal radiation-induced end point, and the risks associated with average skeletal doses of the four transuranium radionuclides, relative to radium, were determined. The relative biological effectiveness (RBE) was calculated for each emitter by dividing its risk coefficient (bone sarcomas per 10(6) mouse-rad) by the risk coefficient for 226Ra. Combined data for males and females in both black and albino mice gave the following values +/- SD for the RBE relative to 226Ra = 1.0: 239Pu = 15.3 +/- 3.9, 241Am = 4.9 +/- 1.4, 249Cf = 5.0 +/- 1.4, and 252Cf = 2.6 +/- 0.8. About 70% of the tumors occurred in the axial skeleton, and the risk coefficient for females averaged about four times higher than for males when all five nuclides were included. The RBE of fission fragment irradiation from 252Cf for cancer induction, relative to alpha irradiation, for the combined data in all of the animals given 252Cf and 249Cf, was 0.02 +/- 0.28, in agreement with the calculated theoretical value of 0.03, based on the ratio of summed track lengths in tissue.

Alpha Particles↗
PubMed1983

Radium retention in mature beagles injected at 5 years of age.

Retention of 226Ra was substantially lower in mature beagles injected at 5 years of age compared to corresponding values for young adult beagles injected at 17 months of age. As with young adults, the percentage retention in mature dogs given about 10 microCi/kg exceeded that in mature dogs given 4 microCi/kg or less. Percentage retention, R, at t days after the injection of 10 microCi/kg in mature beagles could be represented by the equation, R = 64.1e-0.233t + 13.0e-0.0048lt + 22.9e-0.000329t, and for mature beagles given 4 microCi/kg or less, R = 38.8e-0.40t + 30.6e-0.0424t + 11.9e-0.00567t + 18.7e-0.000352t. Measured 222Rn/226Ra ratios in bone were similar in mature and young adults. Roughly 66% of the injected radium was excreted by mature dogs during the first 3 weeks, about two-thirds of the total excretion appearing in the feces. Distribution of 226Ra within the skeleton was similar in mature and young adult beagles.

Age Factors↗
PubMed1983

Radium retention and dosimetry in juvenile beagles.

Retention of administered 226Ra was substantially greater in beagles injected as 3-month-old juveniles than as 1.4-year-old young adults, but the measured 222Rn/226Ra ratio in bone was significantly less in juveniles for about the first 600 days after injection. An equation that describes the total-body biological retention R in beagles injected with 226Ra at 3 months of age at any time t (in days) after injection during the first 6.6 years is R = 0.331e-0.206t + 0.245e-0.00374t + 0.424e-0.000114t. The rate constant of the final term in the equation for juveniles is similar to that for young adults, suggesting that this component reflects the net turnover rate in the slowly remodeling component of adult bone. Compared to young adult beagles, animals injected as juveniles had a greater fraction of their retained 226Ra in parts of the skeleton containing much cortical bone, such as paws, and a smaller fraction in those parts containing much trabecular bone.

Age Factors↗
PubMed1983

Radium retention and dosimetry in the St. Bernard.

The percentage total-body retention (R) of 226Ra was determined in 14 young adult St. Bernards for the first 4 years after injection to be represented by the equation, R = 34.8 e-0.165t + 24.6 e-0.00537t + 40.6 e-0.000503t, where t is the time after injection in days. It was found that the 222Rn/226Ra ratio in the skeleton was similar to that measured previously for young adult beagles given 226Ra. Excretion of injected 226Ra averaged about 32% in the first 2 weeks, with about 2/3 of the total appearing in the feces. St. Bernards appear to retain more 226Ra than do beagles injected at the same age. The last two terms of the retention equation were used to calculate the average skeletal radiation dose rate and cumulative radiation dose normalized to each dog's individual retention measurements. Allowance was made in the calculations for the changing skeletal retention of 222Rn and its radioactive daughters as a function of time.

Alpha Particles↗